Kura Oncology to Report Second Quarter Financial Results
Kura Oncology announced it will report second quarter 2026 financial results on August 12, 2026, followed by a webcast. The company also reported durable clinical activity of its drug candidate darlifarnib plus cabozantinib in renal cell carcinoma patients, with response rates up to 50% and median PFS of 13 months observed in pre-treated, cabozantinib-naïve patients.